| NCT07009860 | RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | RECRUITING | PHASE2 | 2025-06-16 | 2027-08-31 | 2027-03-31 |
| NCT06987513 | RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight | RECRUITING | PHASE2 | 2025-05-15 | 2026-09-30 | 2026-09-30 |
| NCT05989711 | IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-07-27 | 2025-12-30 | 2025-02-28 |
| NCT05295875 | Efficacy and Safety of ALT-801 in the Treatment of Obesity | COMPLETED | PHASE2 | 2022-03-31 | 2023-09-28 | 2023-09-28 |
| NCT05292911 | Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) | COMPLETED | PHASE1 | 2022-03-09 | 2022-10-31 | 2022-10-31 |
| NCT05134662 | ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) | COMPLETED | PHASE1 | 2022-02-01 | 2023-03-09 | 2023-02-03 |
| NCT05006885 | ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) | COMPLETED | PHASE1 | 2021-09-30 | 2022-08-17 | 2022-08-17 |
| NCT04972396 | Pemvidutide (ALT-801) DDI Study in Healthy Volunteers | COMPLETED | PHASE1 | 2021-09-15 | 2022-05-15 | 2022-05-15 |
| NCT04679909 | Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) | COMPLETED | PHASE1 | 2021-02-25 | 2022-12-21 | 2021-12-01 |
| NCT04684914 | HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) | TERMINATED | PHASE2 | 2020-12-26 | 2024-04-17 | 2024-03-27 |
| NCT04561245 | ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability | COMPLETED | PHASE1 | 2020-11-10 | 2021-10-29 | 2021-10-29 |
| NCT04442230 | NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) | TERMINATED | PHASE2 | 2020-10-10 | 2021-02-15 | 2021-02-15 |
| NCT04415749 | NasoShield in Healthy Adults to Study Safety and Immunogenicity | COMPLETED | PHASE1 | 2020-06-15 | 2021-03-15 | 2021-03-15 |
| NCT03352466 | NasoShield Study of Safety and Immunogenicity | COMPLETED | PHASE1 | 2018-01-18 | 2019-05-13 | 2019-05-13 |
| NCT03232567 | Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX | COMPLETED | PHASE2 | 2017-09-18 | 2018-06-15 | 2018-03-07 |
| NCT03163342 | Immune Response Following Seasonal Influenza Vaccination | COMPLETED | PHASE4 | 2017-05-08 | 2018-06-15 | 2017-11-21 |
| NCT02496897 | Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B | COMPLETED | PHASE1 | 2015-07 | 2018-06-05 | 2017-10-13 |
| NCT00755703 | Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine. | COMPLETED | PHASE1 | 2008-10 | 2011-12 | 2009-09 |